Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

Figure 1 FS1 from FGFR mRNA Expression in Cholangiocarcinoma and Its Correlation with <i>FGFR2</i> Fusion Status and Immune Signatures

<p>Supplementary Figure 1</p>

Kaydedildi:

Detaylı Bibliyografya
Yazar:	Vishwajith Sridharan (15047154) (author)
Diğer Yazarlar:	Azfar Neyaz (15047157) (author), Abhijit Chogule (15047160) (author), Islam Baiev (15047163) (author), Stephanie Reyes (15047166) (author), Emily G. Barr Fritcher (15047169) (author), Jochen K. Lennerz (15014703) (author), William Sukov (15047172) (author), Benjamin Kipp (15047175) (author), David T. Ting (15018716) (author), Vikram Deshpande (15047178) (author), Lipika Goyal (15047181) (author)
Baskı/Yayın Bilgisi:	2025
Konular:	Cancer Therapeutic Research and Development Immuno-oncology Clinical Research and Trials Gastrointestinal Cancers Immunotherapy Checkpoint blockade Precision Medicine Translational Research
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller

Supplementary Figures1 from The Ave–Rec Trial: Phase II Trial of PDL1/PD1 Blockade with Avelumab after Chemoradiotherapy for Locally Advanced Resectable T3B-4/N1-2 Rectal Cancer
Yazar:: Michael Michael (15021425)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Yazar:: Robert W. Lentz (17013559)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Yazar:: Robert W. Lentz (17013559)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Yazar:: Robert W. Lentz (17013559)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Yazar:: Robert W. Lentz (17013559)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Yazar:: Robert W. Lentz (17013559)
Baskı/Yayın Bilgisi: (2025)

Supplementary Table 3 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Yazar:: Robert W. Lentz (17013559)
Baskı/Yayın Bilgisi: (2025)

Table 1 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Yazar:: Robert W. Lentz (17013559)
Baskı/Yayın Bilgisi: (2025)

Table 2 from Phase II Clinical Trial and Preclinical Evaluation of a Novel CD47 Blockade Combination in Refractory Microsatellite-Stable Metastatic Colorectal Cancer
Yazar:: Robert W. Lentz (17013559)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Yazar:: Kohei Shitara (15043443)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Yazar:: Kohei Shitara (15043443)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Yazar:: Kohei Shitara (15043443)
Baskı/Yayın Bilgisi: (2025)

Table 1 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Yazar:: Kohei Shitara (15043443)
Baskı/Yayın Bilgisi: (2025)

Table 2 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Yazar:: Kohei Shitara (15043443)
Baskı/Yayın Bilgisi: (2025)

Table 3 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Yazar:: Kohei Shitara (15043443)
Baskı/Yayın Bilgisi: (2025)

Table 4 from Efficacy and Safety of Nivolumab Monotherapy in Patients with High PD-1–Positive CD8/Treg Ratio in Advanced NSCLC and Gastric Cancer: A Phase II, Multicenter Study
Yazar:: Kohei Shitara (15043443)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
Yazar:: Maria Alsina (21718246)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
Yazar:: Maria Alsina (21718246)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
Yazar:: Maria Alsina (21718246)
Baskı/Yayın Bilgisi: (2025)

Table 1 from A Phase II Study of Perioperative Avelumab plus Chemotherapy for Patients with Resectable Gastric Cancer or Gastroesophageal Junction Cancer – The MONEO Study
Yazar:: Maria Alsina (21718246)
Baskı/Yayın Bilgisi: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
Yazar:: Ankita Mitra (17141783)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S10 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S11 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S12 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S13 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S14 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S2 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S3 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S4 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S5 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S6 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S7 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S8 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S9 from FADD Activation in Hepatocellular Carcinoma Potentiates CD8<sup>+ </sup>T-cell Responses and Sensitizes to Immune Checkpoint Inhibitors
Yazar:: Jiahuan Lu (22247140)
Baskı/Yayın Bilgisi: (2025)

Figure S1 from A Phase II Study of Durvalumab for Bacillus Calmette-Guerin (BCG) Unresponsive Urothelial Carcinoma <i>In Situ</i> of the Bladder
Yazar:: Roger Li (17078665)
Baskı/Yayın Bilgisi: (2025)

Figure 1 from Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients
Yazar:: Lauren Polyakov (21672045)
Baskı/Yayın Bilgisi: (2025)

Figure 2 from Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients
Yazar:: Lauren Polyakov (21672045)
Baskı/Yayın Bilgisi: (2025)

Figure 3 from Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients
Yazar:: Lauren Polyakov (21672045)
Baskı/Yayın Bilgisi: (2025)

Figure 4 from Impact of Glucocorticoids on Immune Checkpoint Inhibitor Efficacy and Circulating Biomarkers in Non–Small Cell Lung Cancer Patients
Yazar:: Lauren Polyakov (21672045)
Baskı/Yayın Bilgisi: (2025)